Acne 

Actinic Keratosis 

Aesthetics

Anti-Aging

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

COVID-19

Drug Watch

Dry Cracked Skin

Hidradenitis Suppurativa

Impetigo

Inflamed Skin

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Surgery

Vitiligo

Wound Care

News

Media

2 Minute Drill

Around the Practice

Between The Lines

Case Based Peer Perspective

DermView

Editorial Board News

Expert Interviews

Expert Perspectives

Fellows Face Off

Frontline Forum

Inside the Clinic

Medical World News

Partner Perspectives

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Viewpoints

Webinars

Conferences

Conference Coverage

Conference Listing

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Image IQ

Interactive Tools

Job Board

Polls

Editorial Advisory Board

Partnerships

Subscribe

Print Subscription

eNewsletter

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Articles

Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.

Alan Irvine, MD, DSc: Atopic Dermatitis and the Biological Clock

 and joined the MJH Life Sciences team in June 2022. She attended Otterbein University in Westerville, Ohio, and earned a Bachelor of Arts degree in literary studies with minors in creative writing and film studies. Prior to health care news, Kaitlyn worked in industrial marketing. She enjoys cooking, reading, and tending to her house plants. 

The promising data on upadacitinib was presented at the 2023 Revolutionizing Vitiligo Virtual Conference  

Upadacitinib for Vitiligo Improves Patient Health-Related QoL After 24 Weeks  

Keep up with the latest headlines in dermatology from the past week, including efficacy of nemolizumab in prurigo nodularis, the addition of a skin bank in northern India where skin banks are scarce, and more.

Derm In The News: December 3-9

ICYMI, this week we had articles about upcoming conferences in 2024, the potential causal relationship between pure hypercholesterolemia and psoriasis, the first patient dosed in Kymera's phase 2 AD trial, and more. 

The Weekly Roundup: December 4-8

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times and Multimedia Medical, LLC

Twitter

Facebook

Linkedin

Topics

Acne

BPDCN

Hair & Scalp

Rosacea

Skin Cancer (Melanoma)

Skin Cancer (Non-Melanoma)

1rem

Authors

Nichole Tucker, MA, is the Web Editor for Targeted Oncology. Tucker received her Bachelor of Arts in Mass Communications from Virginia State University and her Master of Arts in Media & International Conflict from University College Dublin.

A coprimary end point in the phase 3 LEAP-010 study will not be met.

LEAP-010 Study Discontinued for Patients with PD-L1-Expressing HNSCC